METHODS: We evaluated the efficacy and safety of nirmatrelvir/ritonavir and molnupiravir in preventing severe illness and death using our database of 457 patients with cancer and COVID-19 from Brown University-affiliated hospitals.
RESULTS: Sixty-seven patients received nirmatrelvir/ritonavir or molnupiravir and were compared to 45 concurrent controls who received no antiviral treatment despite being eligible to receive it. Administration of nirmatrelvir/ritonavir or molnupiravir was associated with improved survival and lower 90-day all-cause and COVID-19-attributed mortality (p < 0.05) and with lower peak O2 requirements (ordinal odds ratio [OR] 1.52, 95% confidence interval [CI] 0.92-2.56).
CONCLUSIONS: Acknowledging the small size of our sample as a limitation, we concluded that early antiviral treatment might be beneficial to immunocompromised individuals, particularly those with cancer, when infected with SARS-CoV-2. Larger-scale, well-stratified studies are needed in this patient population.
方法:我们使用来自布朗大学附属医院的457例癌症和COVID-19患者的数据库,评估了尼马特雷韦/利托那韦和莫诺比拉韦预防严重疾病和死亡的有效性和安全性。
结果:67名患者接受了尼马特雷韦/利托那韦或莫诺比拉韦,并与45名尽管有资格接受抗病毒治疗但未接受抗病毒治疗的并发对照进行了比较。服用尼马特雷韦/利托那韦或莫诺比拉韦与生存率提高、90天全因死亡率和COVID-19归因死亡率降低相关(p<0.05),峰值O2需求降低(序数比值比[OR]1.52,95%置信区间[CI]0.92-2.56)。
结论:承认我们的样本规模较小是一个限制,我们得出结论,早期抗病毒治疗可能对免疫功能低下的个体有益,尤其是那些患有癌症的人,当感染SARS-CoV-2时。规模较大,在这一患者人群中需要进行良好的分层研究.